Abstract

Background/objectivesVascular damage contributes to the high cardiovascular morbidity and mortality in end-stage renal disease (ESRD). Increased aortic stiffness measured by carotid-femoral pulse wave velocity (cf-PWV) is a strong and independent predictor of the cardiovascular risk in ESRD patients. Recently, there has been considerable interest in developing strategies to lessen the progression of arterial stiffness in ESRD patients using cf-PWV as a tool to monitor therapeutic responses, but their benefit on the long-term cardiovascular risk is not known. Appraisal of the effects of existing stiffness-based interventions on the cf-PWV would facilitate selecting optimal therapies to be tested in randomized clinical trials. The aim of this systematic review will be to evaluate the impact of arterial stiffness-based interventions on the cf-PWV in ESRD patients. Secondarily, for each intervention, we will determine the minimal duration needed to achieve a significant reduction of cf-PWV, the minimal cf-PWV reduction threshold or effect size, and adverse events.Methods/designThis review will be conducted using MEDLINE, EMBASE, and EBM Reviews. We will select clinical trials and observational studies (cohort, case-control, and before/after studies and case series) that evaluated pharmacologic or non-pharmacologic interventions in which the primary effect is to improve structural and/or dynamic components of arterial stiffness in adults with stage 5 chronic kidney disease. The primary outcome of interest will be cf-PWV. Study selection and data collection will be performed by two reviewers. Validated tools will be used to assess the methodological quality and risk of bias among different study designs. We will describe all included citations according to study characteristics, methodological quality, and outcomes. Suitability for meta-analysis will be determined by the degree of clinical and statistical heterogeneity between studies. If appropriate, we will calculate effect estimates by obtaining the relative risks with 95 % confidence intervals pooled according to study design using a random effects model.DiscussionThis review will summarize evidence regarding effects of interventions targeting arterial stiffness in ESRD patients. Our results will inform clinicians and researchers on the type of existing arterial stiffness-based interventions for ESRD patients and their potential efficacy and safety, with a goal to guide future clinical trials aimed at reducing adverse cardiovascular events.Systematic review registrationPROSPERO CRD42016033463Electronic supplementary materialThe online version of this article (doi:10.1186/s13643-016-0286-5) contains supplementary material, which is available to authorized users.

Highlights

  • Chronic kidney disease (CKD) is a major health burden worldwide because of its high prevalence and associated risk of end-stage renal disease (ESRD), cardiovascular disease, and premature death

  • Our results will inform clinicians and researchers on the type of existing arterial stiffness-based interventions for ESRD patients and their potential efficacy and safety, with a goal to guide future clinical trials aimed at reducing adverse cardiovascular events

  • The primary objective of this review is to evaluate the impact of stiffness-based therapeutic interventions on the reduction of carotid-femoral pulse wave velocity (cf-pulse wave velocity (PWV)) in ESRD patients

Read more

Summary

Introduction

Chronic kidney disease (CKD) is a major health burden worldwide because of its high prevalence and associated risk of end-stage renal disease (ESRD), cardiovascular disease, and premature death. In 2013, 956,200 deaths worldwide were reported to be directly attributed to CKD, representing a 134.6 % increase from those reported in 1990 [2]. The high prevalence of CKD has led to an increased prevalence of ESRD worldwide and elevated health care costs. It is estimated that in the period from 2000 to 2007, the total direct Medicare costs for ESRD in the USA alone increased from $ 12.2 billion to $ 20.8 billion [3]. In Canada, the number of people with ESRD in the last decade rose from 29,540 to 41,252, representing an increase of 40 % [4]. By the end of 2013, 23,926 Canadians with ESRD were receiving some form of dialysis, but only 15 % of those were on the waiting list for a renal transplant [4]

Objectives
Methods
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.